Releases Details

Gaithersburg, Maryland – May 29, 2018 MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA Cell Therapy, will present at the 2018 BIO International Convention (Boston Convention Center) on June 6, 2018, at 2:45 p.m. ET.

Ms. Bowes will present and discuss MaxCyte’s next-generation autologous CAR (chimeric antigen receptor) therapies in a presentation entitled, “Novel CAR Platform: The Next Generation Autologous CAR Therapies in Oncology.” The presentation will focus on how MaxCyte’s breakthrough CARMA platform in immuno-oncology has the ability to engineer transient persistence to mitigate off-tumor toxicity and significantly reduce the turnaround time of autologous cell therapy to patients.

“It’s exciting to have the opportunity at the 2018 BIO International Convention to share the progress we’ve made in advancing our novel and proprietary CARMA platform and CAR therapy drug candidates,” said Ms. Bowes. “Our CARMA platform’s approach has potential in a broad range of targets and cancers, including solid tumors, while reducing potential adverse events that have been evident with previous CAR technologies. This is significant, now more than ever, as our goal is to advance our first CAR therapy into the clinic this year.”

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. More information can be found at www.convention.bio.org/.

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered program licenses in cell therapy including more than 20 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

For more information, visit www.maxcyte.com.

###